MedTrace Logo

Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis

NCT00439712 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-01-15

No results posted yet for this study

Summary

The purpose of this study is to show that in patients suffering from perennial allergic rhinitis levocetirizine 5 mg OD relieves nasal obstruction. Furthermore the study is to investigate how relevant for these patients their nasal obstruction and the effect of levocetirizine on their nasal obstruction are.

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Levocetirizine

1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days

DRUG

Placebo

1 placebo tablet OD in the morning for 29+/-4 days

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Institut für Atemwegsforschung GmbH

    lead INDUSTRY

Principal Investigators

  • Claus Bachert, MD, PhD · Institut für Atemwegsforschung GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439712 on ClinicalTrials.gov